Overview
Spherix’s new coverage of the irritable bowel syndrome treatment area addresses the arrival of a new mechanism of action to this more mature market. We cover how an innovative small molecule treatment could change gastroenterologists’ and primary care physician’s attitudes and algorithms in managing these patients.
Services Available
Prepping for the pipeline
Irritable Bowel Syndrome Gastroenterology Perspective (US)
Irritable Bowel Syndrome PCP Perspective (US)
Benchmarking new brand performance
Isbrela (Ardelyx) in Irritable Bowel Syndrome (US)
Gastroenterology Biosimilars Today and Tomorrow (US)
Multi Specialty Impact of COVID 19 Gastroenterology (US)
PCP Treatment of Gastroenterology (US)
Pediatric Gastroenterology (US)
The Business of Gastroenterology (US)
The Impact of Biosimilar Usage in Gastroenterology (US)